• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Ponatinib-induced psoriasis treated with tildrakizumab.

作者信息

Mueller Kyle, Goldenberg Alicia, Kuraitis Drew

机构信息

Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York.

Department of Dermatology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

出版信息

JAAD Case Rep. 2025 May 28;62:69-71. doi: 10.1016/j.jdcr.2025.04.038. eCollection 2025 Aug.

DOI:10.1016/j.jdcr.2025.04.038
PMID:40678003
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12269876/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c0f/12269876/7db93cac4d7b/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c0f/12269876/e334099f3b9f/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c0f/12269876/7bdc2e0d8469/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c0f/12269876/7db93cac4d7b/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c0f/12269876/e334099f3b9f/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c0f/12269876/7bdc2e0d8469/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c0f/12269876/7db93cac4d7b/gr3.jpg

相似文献

1
Ponatinib-induced psoriasis treated with tildrakizumab.用替拉珠单抗治疗波纳替尼诱发的银屑病。
JAAD Case Rep. 2025 May 28;62:69-71. doi: 10.1016/j.jdcr.2025.04.038. eCollection 2025 Aug.
2
Tildrakizumab in the treatment of psoriasis: latest evidence and place in therapy.替拉珠单抗治疗银屑病：最新证据及在治疗中的地位
Ther Adv Chronic Dis. 2019 Aug 12;10:2040622319865658. doi: 10.1177/2040622319865658. eCollection 2019.
3
Impact of tildrakizumab on the quality of life of patients with moderate-to-severe psoriasis: a 36-week prospective monocentric real-life observational study.替拉珠单抗对中度至重度银屑病患者生活质量的影响：一项为期36周的前瞻性单中心真实世界观察性研究。
Clin Exp Dermatol. 2025 Feb 24;50(3):544-550. doi: 10.1093/ced/llae433.
4
Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.替西单抗（MK-3222），一种抗白细胞介素-23p19 单克隆抗体，在一项 IIb 期随机安慰剂对照试验中改善了银屑病。
Br J Dermatol. 2015 Oct;173(4):930-9. doi: 10.1111/bjd.13932. Epub 2015 Oct 15.
5
Retrospective Analysis in Patients With Moderate to Severe Plaque Psoriasis Treated With Tildrakizumab: Real-Life Clinical Data.使用替拉珠单抗治疗中度至重度斑块状银屑病患者的回顾性分析：真实临床数据
J Psoriasis Psoriatic Arthritis. 2022 Apr;7(2):55-59. doi: 10.1177/24755303221077211. Epub 2022 Mar 29.
6
Tildrakizumab Treatment Patterns in Adults With Moderate-to-Severe Plaque Psoriasis: A Retrospective Analysis From the Canadian Patient Support Program.中度至重度斑块状银屑病成人患者的替拉珠单抗治疗模式：来自加拿大患者支持项目的回顾性分析
Dermatol Ther (Heidelb). 2025 May 29. doi: 10.1007/s13555-025-01434-x.
7
Patient-Reported Well-Being in Value-Based Routine Care Using Tildrakizumab: 52-week Interim Data of the Phase IV Positive Study.使用替拉珠单抗的基于价值的常规护理中患者报告的健康状况：IV期阳性研究的52周中期数据
Psoriasis (Auckl). 2025 Jun 28;15:243-259. doi: 10.2147/PTT.S526748. eCollection 2025.
8
Tildrakizumab: A Review of Phase II and III Clinical Trials.替度鲁单抗：II 期和 III 期临床试验综述。
Ann Pharmacother. 2019 Apr;53(4):413-418. doi: 10.1177/1060028018809522. Epub 2018 Oct 20.
9
The potential utility of tildrakizumab: an interleukin-23 inhibitor for the treatment of psoriasis.替拉珠单抗的潜在效用：一种用于治疗银屑病的白细胞介素-23抑制剂。
Expert Opin Investig Drugs. 2017 Feb;26(2):243-249. doi: 10.1080/13543784.2017.1274734. Epub 2017 Jan 1.
10
Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64-week phase 3 study (reSURFACE 1).替西罗莫司单抗治疗中度至重度斑块状银屑病日本患者的疗效和安全性：一项 64 周 3 期研究（reSURFACE 1）的结果。
J Dermatol. 2021 Jun;48(6):853-863. doi: 10.1111/1346-8138.15789. Epub 2021 Feb 25.

本文引用的文献

1
Psoriasis in the Era of Targeted Cancer Therapeutics: A Systematic Review on De Novo and Pre-existing Psoriasis in Oncologic Patients Treated with Emerging Anti-neoplastic Agents.靶向癌症治疗时代的银屑病：关于接受新型抗肿瘤药物治疗的肿瘤患者新发和既往存在银屑病的系统评价
Dermatol Ther (Heidelb). 2024 Jul;14(7):1755-1766. doi: 10.1007/s13555-024-01198-w. Epub 2024 Jun 22.
2
Targeting IL-17A enhances imatinib efficacy in Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia.靶向白细胞介素-17A 可增强费城染色体阳性 B 细胞急性淋巴细胞白血病伊马替尼的疗效。
Nat Commun. 2024 Jan 3;15(1):203. doi: 10.1038/s41467-023-44270-3.
3
Ponatinib: An update on its drug targets, therapeutic potential and safety.
泊那替尼：药物靶点、治疗潜力和安全性的最新进展。
Biochim Biophys Acta Rev Cancer. 2023 Sep;1878(5):188949. doi: 10.1016/j.bbcan.2023.188949. Epub 2023 Jul 1.
4
Tyrosine kinase inhibitors can activate the NLRP3 inflammasome in myeloid cells through lysosomal damage and cell lysis.酪氨酸激酶抑制剂可通过溶酶体损伤和细胞裂解激活髓系细胞中的NLRP3炎性小体。
Sci Signal. 2023 Jan 17;16(768):eabh1083. doi: 10.1126/scisignal.abh1083.
5
Novel Therapies in Plaque Psoriasis: A Review of Tyrosine Kinase 2 Inhibitors.斑块状银屑病的新型疗法：酪氨酸激酶2抑制剂综述
Dermatol Ther (Heidelb). 2023 Feb;13(2):417-435. doi: 10.1007/s13555-022-00878-9. Epub 2023 Jan 2.
6
Phospholipase A2 enzymes represent a shared pathogenic pathway in psoriasis and pityriasis rubra pilaris.磷脂酶 A2 酶在银屑病和毛发红糠疹中代表了一个共同的致病途径。
JCI Insight. 2021 Oct 22;6(20):e151911. doi: 10.1172/jci.insight.151911.
7
Efficacy and safety of tildrakizumab 100 mg for plaque psoriasis in patients randomized to treatment continuation vs treatment withdrawal with retreatment upon relapse in reSURFACE 1.在reSURFACE 1研究中，随机接受持续治疗与停药并在复发时重新治疗的斑块状银屑病患者使用100毫克替拉珠单抗的疗效和安全性。
J Eur Acad Dermatol Venereol. 2021 Aug;35(8):e526-e528. doi: 10.1111/jdv.17124. Epub 2021 Feb 12.
8
Tildrakizumab for psoriasis.替拉珠单抗治疗银屑病。
Aust Prescr. 2019 Feb;42(1):40-41. doi: 10.18773/austprescr.2018.075. Epub 2018 Dec 13.
9
Extracellular ATP and IL-23 Form a Local Inflammatory Circuit Leading to the Development of a Neutrophil-Dependent Psoriasiform Dermatitis.细胞外 ATP 和 IL-23 形成局部炎症回路，导致中性粒细胞依赖性银屑病样皮炎的发生。
J Invest Dermatol. 2018 Dec;138(12):2595-2605. doi: 10.1016/j.jid.2018.05.018. Epub 2018 Jun 2.
10
An IL-17-dominant immune profile is shared across the major orphan forms of ichthyosis.白细胞介素-17主导的免疫特征在主要的鱼鳞病罕见类型中是共有的。
J Allergy Clin Immunol. 2017 Jan;139(1):152-165. doi: 10.1016/j.jaci.2016.07.019. Epub 2016 Aug 20.